Literature DB >> 22134084

Radar commentary: Use of linear no-threshold hypothesis in radiation protection regulation in the United States.

Jeffry A Siegel1, Michael G Stabin.   

Abstract

Radiation protection recommendations advanced by the International Commission on Radiological Protection and National Council on Radiation Protection and Measurements, and many times adopted into regulations by the United States Nuclear Regulatory Commission, need to be based on scientifically justified assumptions and conclusions. The linear no-threshold model assigns risk to every radiation exposure above zero dose and is the current basis for setting radiation protection standards worldwide. This hypothesis is vigorously challenged by many individuals but just as vigorously defended in spite of the uncertainties surrounding health effects at low dose levels. It is clear that at radiation doses below 100 mSv, the effects, if any, are so low as to be unobservable and perhaps, therefore, unknowable. However, the linear no-threshold hypothesis is used routinely to formulate regulatory dose limits for workers and the general public and to derive stochastic radiogenic risk estimates at low doses. This note will show that while the linear no-threshold hypothesis may play a legitimate role in setting radiation protection standards and operating policies, such as establishing dose limits or as part of an operational "as low as is reasonably achievable" (ALARA) policy, it is inappropriate for use in estimating possible cancer risks associated with low-level radiation exposures. It will also demonstrate that the raising, not lowering, of current regulatory dose limits is more solidly supported by the actual observed data on radiation dose and effects. The authors submit that the misuse of the linear no-threshold model for predicting radiation effects in exposed individuals and populations should be discontinued.

Entities:  

Mesh:

Year:  2012        PMID: 22134084     DOI: 10.1097/HP.0b013e318228e5b4

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  8 in total

1.  The Fukushima radiological emergency and challenges identified for future public health responses.

Authors:  Charles W Miller
Journal:  Health Phys       Date:  2012-05       Impact factor: 1.316

2.  ALARA, image gently and CT-induced cancer.

Authors:  Mervyn D Cohen
Journal:  Pediatr Radiol       Date:  2015-02-14

3.  Epidemiology Without Biology: False Paradigms, Unfounded Assumptions, and Specious Statistics in Radiation Science (with Commentaries by Inge Schmitz-Feuerhake and Christopher Busby and a Reply by the Authors).

Authors:  Bill Sacks; Gregory Meyerson; Jeffry A Siegel
Journal:  Biol Theory       Date:  2016-06-17

Review 4.  Radiobiology in Cardiovascular Imaging.

Authors:  Pat Zanzonico; Lawrence Dauer; H William Strauss
Journal:  JACC Cardiovasc Imaging       Date:  2016-12

5.  Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response.

Authors:  R Lall; S Ganapathy; M Yang; S Xiao; T Xu; H Su; M Shadfan; J M Asara; C S Ha; I Ben-Sahra; B D Manning; J B Little; Z-M Yuan
Journal:  Cell Death Differ       Date:  2014-02-28       Impact factor: 15.828

6.  Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.

Authors:  Christian H Pfob; Sibylle Ziegler; Frank Philipp Graner; Markus Köhner; Sylvia Schachoff; Birgit Blechert; Hans-Jürgen Wester; Klemens Scheidhauer; Markus Schwaiger; Tobias Maurer; Matthias Eiber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-20       Impact factor: 9.236

7.  Role of Computed Tomography Scan in Dental Trauma: A Cross-Sectional Study.

Authors:  Feng Li; Jun Li; Deming Zhang; Feng Wu
Journal:  Dose Response       Date:  2018-08-23       Impact factor: 2.658

Review 8.  The Response of Living Organisms to Low Radiation Environment and Its Implications in Radiation Protection.

Authors:  Mauro Belli; Luca Indovina
Journal:  Front Public Health       Date:  2020-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.